Navigation Links
XBiotech Expands Portfolio to Include Biosimilars
Date:2/26/2013

AUSTIN, Texas, Feb. 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product. Entering into the biosimilar space will complete what XBiotech considers is its strategic portfolio of therapeutic antibodies. The Company believes that its manufacturing technology will lower production costs for biological products by an order of magnitude compared to other developers of generic biologics. Moreover, the Company claims that the flexibility and short lead-times needed to build production capacity is ideally suited for addressing the uncertain market conditions for biosimilars. The Company aims to enter into clinical trials with its first biosimilar product within the next year and launch into the market place by 2017.

(Logo: http://photos.prnewswire.com/prnh/20121017/MM95359LOGO)

"With our ability to manufacture antibody product at ultra-low costs, our aim is to make XBiotech the most competitive provider of biosimilar products in the world," said John Simard , president and CEO of XBiotech. "This is a logical next step to round out our antibody assets and fully exploit XBiotech's antibody commercialization platform."

There are a number of different biosimilar antibodies expected to hit the market beginning in 2014, including generic versions of Avastin®, Herceptin®, Remicade™, Rituxan®, and others.  These therapeutics currently represent the majority of revenues from global sales of antibodies, of more than $40 billion.  The potential to capture significant share of this market is luring a number of players, including heavy-weight producers of branded biologics, such as Amgen, and diverse entrants, such as Samsung, into the biosimilar development. However, with the large number of developers there remains considerable uncertainty about how market share is going to be divided, once a number of competing products hit the market.

Simard added that "In the biosimilar space cost competitiveness is going to be crucial to the success of these products. Market share is going to be driven by the ability to provide these products to the end user at lower costs than the competitor's. Developers capable of dramatically reducing cost of goods and establishing innovative distribution strategies will ultimately be able to dominate the biosimilar market. We believe XBiotech is well positioned to take advantage of this opportunity."

About XBiotech
XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1α, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies.  Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for therapeutic antibodies.  For more information on how XBiotech is advancing human monoclonal antibody therapy please visit www.xbiotech.com.

Contact: 
Investors: 
Erika Geimonen
XBiotech
info@xbiotech.com
512.386.2906
Media:
Aaron DeLucia
Porter Novelli
aaron.delucia@porternovelli.com
512.241.2249


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
2. RF Technologies expands product offering with RTLS
3. Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing
4. Superlift Expands Line of Stainless Steel Powered Pallet Trucks
5. UMBC Expands Offerings at The Universities at Shady Grove with Biotechnology Graduate Program
6. 1DegreeBio Expands its Product Review Platform Across Life Sciences
7. Genuine Bio-Fuel Inc. Expands Operations to Puerto Rico
8. Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
9. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
10. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
11. Why Texas is #1 in Business: Local BioTech Company Expands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):